Sulantrix
Small-molecule drug discovery targeting pseudokinase ("zombie" protein) classes for hard-to-treat diseases
Highlights
- Young companyFounded 2022
- New on EvolcAdded 2026-11-10
About Sulantrix
Sulantrix is a UK biotech company developing small-molecule drugs that modulate pseudokinases, a class of 'zombie' proteins that lack normal catalytic activity. Its stated focus is on diseases where treatment options are missing or existing medicines have stopped working.
The pseudokinase targets it pursues are described as relevant to hard-to-treat solid and blood cancers, fibrosis, neurodegeneration and age-related diseases. The company's medicines are intended either as primary treatments or to be used alongside existing therapies.
The company is registered in the United Kingdom and was founded in 2022. Its scientific advisory board includes academics from the universities of Dundee, Leeds, Cambridge, Glasgow and Georgia (USA), and the Babraham Institute.
Product: Small-molecule drug candidates targeting pseudokinase proteins for cancer, fibrosis, neurodegeneration and age-related diseases.
Jobs at Sulantrix
More biotech & pharma companies
Super B Plus Group
Pharmaceutical and medical device sourcing and wholesale supply for UK pharmacies, NHS Trusts and clinical trial sponsorsNew on EvolcSurescreen Scientifics
EDNA and molecular species identification lab testing samples for the UK ecology and planning sectorNew on EvolcSygnature Discovery
Contract drug discovery services for biotech and pharma partners in the US, Canada, UK and EuropeSyngensys
Synthetic gene promoters and custom genetic components for gene and cell therapy developers and biomanufacturersNew on EvolcSynthace
Experiment design, lab automation and AI-ready data software for drug discovery and life science R&D teamsT-Cypher Bio
Develops immune engager drugs for cancer and autoimmune diseases, built on proprietary wet-lab and computational platformsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Privacy & consent
- IubendaHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.